Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

[1]  M. Speicher,et al.  Persistence of DNA threads in human anaphase cells suggests late completion of sister chromatid decatenation , 2007, Chromosoma.

[2]  T. Šolmajer,et al.  Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. , 2007, Current medicinal chemistry.

[3]  Anthony Maxwell,et al.  Energy coupling in type II topoisomerases: why do they hydrolyze ATP? , 2007, Biochemistry.

[4]  Morten O. Christensen,et al.  C-Terminal regions of topoisomerase IIα and IIβ determine isoform-specific functioning of the enzymes in vivo , 2007, Nucleic acids research.

[5]  T. Bestor,et al.  The decatenation checkpoint , 2007, British Journal of Cancer.

[6]  R. Shoemaker,et al.  A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase IIα by Substituted Purine Analogs , 2006, Molecular Pharmacology.

[7]  Iha Park,et al.  Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. , 2006, Experimental cell research.

[8]  D. J. Clarke,et al.  A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin. , 2006, Genes & development.

[9]  Y. Toyoda,et al.  Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance. , 2006, Molecular biology of the cell.

[10]  T. Bestor,et al.  Decatenation checkpoint deficiency in stem and progenitor cells. , 2005, Cancer cell.

[11]  G. Verdine,et al.  Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase* , 2005, Journal of Biological Chemistry.

[12]  J M Berger,et al.  Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. , 2005, Biochemical Society transactions.

[13]  Haico van Attikum,et al.  The histone code at DNA breaks: a guide to repair? , 2005, Nature Reviews Molecular Cell Biology.

[14]  D. Scudiero,et al.  Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. , 2005, Cancer research.

[15]  Junjie Chen,et al.  BRCA1 participates in DNA decatenation , 2005, Nature Structural &Molecular Biology.

[16]  D. M. Olive,et al.  A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. , 2005, Analytical biochemistry.

[17]  Kim Nasmyth,et al.  Shugoshin Prevents Dissociation of Cohesin from Centromeres During Mitosis in Vertebrate Cells , 2005, PLoS biology.

[18]  A. Porter,et al.  Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. , 2004, Molecular biology of the cell.

[19]  R. Margolis,et al.  Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. , 2004, Molecular cell.

[20]  A. Mikhailov,et al.  Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway , 2004, The Journal of cell biology.

[21]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[22]  K. Yanagisawa,et al.  Identification of Decatenation G2 Checkpoint Impairment Independently of DNA Damage G2 Checkpoint in Human Lung Cancer Cell Lines , 2004, Cancer Research.

[23]  F. Palitti,et al.  Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs. , 2004, Current medicinal chemistry. Anti-cancer agents.

[24]  J. Berger,et al.  Erratum: Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 (Proceedings of the National Academy of Sciences of the United States of America (September 16, 2003) 100:19 (10629-10634)) , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Mateos,et al.  DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. , 2003, Mutation research.

[26]  E. Sakamoto-Hojo,et al.  Translocation analysis by the FISH-painting method for retrospective dose reconstruction in individuals exposed to ionizing radiation 10 years after exposure. , 2003, Mutation research.

[27]  J. Berger,et al.  Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Escargueil,et al.  Catalytic topoisomerase II inhibitors in cancer therapy. , 2003, Pharmacology & therapeutics.

[29]  J. Oshima,et al.  The G2-phase decatenation checkpoint is defective in Werner syndrome cells. , 2003, Cancer research.

[30]  N. Akimitsu,et al.  Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[31]  B. Knudsen,et al.  A Human Topoisomerase IIα Heterodimer with Only One ATP Binding Site Can Go through Successive Catalytic Cycles* , 2003, The Journal of Biological Chemistry.

[32]  J. Lakey,et al.  Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIbeta: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability. , 2002, Nucleic acids research.

[33]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[34]  Hanlin Gao,et al.  Topoisomerase II Poisoning by ICRF-193* , 2001, The Journal of Biological Chemistry.

[35]  R. Paules,et al.  The human decatenation checkpoint , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Wei Li,et al.  DNA topoisomerase IIβ and neural development , 2000 .

[37]  K. Hande.  Clinical applications of anticancer drugs targeted to topoisomerase II. , 1998, Biochimica et biophysica acta.

[38]  B. Hill,et al.  Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents , 1998 .

[39]  S. Kenwrick,et al.  Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. , 1998, Cancer research.

[40]  C V Smith,et al.  The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography. , 1996, The EMBO journal.

[41]  D. J. Clarke,et al.  A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells , 1994, Nature.

[42]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[43]  D. Botstein,et al.  DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage , 1989, Molecular and cellular biology.

[44]  T. Uemura,et al.  DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe , 1987, Cell.

[45]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[46]  P. A. Lanzetta,et al.  An improved assay for nanomole amounts of inorganic phosphate. , 1979, Analytical biochemistry.

[47]  K. Kohn,et al.  Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. , 1979, Biochimica et biophysica acta.

[48]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[49]  B. Hill,et al.  Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. , 1998, Biochemical pharmacology.